Stock comparison
Haemonetics
Iovance Biotherapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
IOVA
Iovance Biotherapeutics
Market cap
$1.47B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | IOVA | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 24F | HAE |
| Benjamin Graham | 85A | 41D | HAE |
| Philip Fisher |
Side-by-side metrics
| Metric | HAE | IOVA |
|---|---|---|
| Market cap | $2.98B | $1.47B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | - |
| ROIC (TTM) | 8.37% | -45.33% |
| Gross margin | 55.74% | 114.51% |
| Net margin | 7.29% | -123.9% |
| Revenue CAGR 5y | 7.65% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- ROIC (TTM)8.37%vs -45.33%+118%
- Net margin7.29%vs -123.9%+106%
- Market cap$2.98Bvs $1.47B+51%
IOVA leads on
More like IOVA
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.